Page 83 - AN-4-2

Advanced Neurology Brain bioavailability of targeted protein degraders

121. Tiruppathi C, Song W, Bergenfeldt M, Sass P, Malik AB. Gp60 protein binding measurement for highly bound compounds
activation mediates albumin transcytosis in endothelial using the dilution method. AAPS J. 2022;25(1):7.
cells by tyrosine kinase-dependent pathway. J Biol Chem. doi: 10.1208/s12248-022-00774-2
1997;272(41):25968-25975.
132. Isbell J, Yuan D, Torrao L, Gatlik E, Hoffmann L, Wipfli P.
doi: 10.1074/jbc.272.41.25968
Plasma protein binding of highly bound drugs determined
122. Minshall RD, Sessa WC, Stan RV, Anderson RGW, Malik AB. with equilibrium gel filtration of nonradiolabeled
Caveolin regulation of endothelial function. Am J Physiol compounds and LC-MS/MS detection. J Pharm Sci.
Lung Cell Mol Physiol. 2003;285(6):L1179-L1183. 2019;108(2):1053-1060.
doi: 10.1152/ajplung.00242.2003 doi: 10.1016/j.xphs.2018.10.004
123. Summerfield SG, Yates JWT, Fairman DA. Free drug 133. Smith QR, Fisher C, Allen DD. The role of plasma protein
theory - no longer just a hypothesis? Pharm Res. binding in drug delivery to brain. In: Kobiler D, Lustig S,
2022;39(2):213-222. Shapira S, editors. Blood-Brain Barrier. Boston, MA:
Springer; 2001.
doi: 10.1007/s11095-022-03172-7
doi: 10.1007/978-1-4615-0579-2_25
124. Volak LP, Duevel HM, Humphreys S, et al. Industry
perspective on the pharmacokinetic and absorption, 134. Pardridge WM, Fierer G. Transport of tryptophan into brain
distribution, metabolism, and excretion characterization of from the circulating, albumin-bound pool in rats and in
heterobifunctional protein degraders. Drug Metab Dispos. rabbits. J Neurochem. 1990;54(3):971-976.
2023;51(7):792-803.
doi: 10.1111/j.1471-4159.1990.tb02345.x
doi: 10.1124/dmd.122.001154
135. Pardridge WM. Recent advances in blood-brain barrier
125. Bohnert T, Gan LS. Plasma protein binding: From discovery transport. Annu Rev Pharmacol Toxicol. 1988;28:25-39.
to development. J Pharm Sci. 2013;102(9):2953-2994.
doi: 10.1146/annurev.pa.28.040188.000325
doi: 10.1002/jps.23614
136. de Lange ECM, Danhof M. Considerations in the use of
126. Pardridge WM, Sakiyama R, Fierer G. Transport of cerebrospinal fluid pharmacokinetics to predict brain target
propranolol and lidocaine through the rat blood-brain concentrations in the clinical setting: Implications of the
barrier. Primary role of globulin-bound drug. J Clin Invest. barriers between blood and brain. Clin Pharmacokinet.
1983;71(4):900-908. 2002;41(10):691-703.
doi: 10.1172/jci110844 doi: 10.2165/00003088-200241100-00001
127. Videbaek C, Ott P, Paulson OB, Knudsen GM. Blood-brain 137. Tonduru AK, Kumar Adla S, Huttunen KM,
barrier transport and protein binding of flumazenil and Kronenberger T, Poso A. Comparative modelling of organic
iomazenil in the rat: Implications for neuroreceptor studies. anion transporting polypeptides: Structural insights and
J Cereb Blood Flow Metab. 1999;19(9):948-955. comparison of binding modes. Molecules. 2022;27(23):8531.
doi: 10.1097/00004647-199909000-00002 doi: 10.3390/molecules27238531
128. Jolliet P, Simon N, Brée F, et al. Blood-to-brain transfer of 138. Pastan I, Gottesman MM, Ueda K, Lovelace E,
various oxicams: Effects of plasma binding on their brain Rutherford AV, Willingham MC. A retrovirus carrying an
delivery. Pharm Res. 1997;14(5):650-656. MDR1 cDNA confers multidrug resistance and polarized
expression of P-glycoprotein in MDCK cells. Proc Natl Acad
doi: 10.1023/a:1012165414610
Sci U SA. 1988;85(12):4486-4490.
129. Lin TH, Sawada Y, Sugiyama Y, Iga T, Hanano M. Effects of
albumin and alpha 1-acid glycoprotein on the transport of doi: 10.1073/pnas.85.12.4486
imipramine and desipramine through the blood-brain barrier 139. Tang F, Horie K, Borchardt RT. Are MDCK cells transfected
in rats. Chem Pharm Bull (Tokyo). 1987;35(1):294-301. with the human MDR1 gene a good model of the human
intestinal mucosa? Pharm Res. 2002;19(6):765-772.
doi: 10.1248/cpb.35.294
doi: 10.1023/a:1016140429238
130. Urien S, Pinquier JL, Paquette B, Chaumet-Riffaud P,
Kiechel JR, Tillement JP. Effect of the binding of isradipine 140. Kuteykin-Teplyakov K, Luna-Tortós C, Ambroziak K,
and darodipine to different plasma proteins on their transfer Löscher W. Differences in the expression of endogenous
through the rat blood-brain barrier. Drug binding to efflux transporters in MDR1-transfected versus wildtype
lipoproteins does not limit the transfer of drug. J Pharmacol cell lines affect P-glycoprotein mediated drug transport. Br J
Exp Ther. 1987;242(1):349-353. Pharmacol. 2010;160(6):1453-1463.
131. Ryu S, Tess D, Di L. Addressing the accuracy of plasma doi: 10.1111/j.1476-5381.2010.00801.x

Volume 4 Issue 2 (2025) 77 doi: 10.36922/an.5140